The phosphorylation specificity of B-RAFWT, B-RAFD594V, B-RAFV600E and B-RAFK601E kinases: An in silico study

Journal of Molecular Graphics and Modelling

Volumn 28, Issue 7, 2010, Pages 598-603

  Fratev, Filip ^a   Jónsdóttir, Svava Ósk ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

B RAF; B RAFV600E; GRID; Kinase; Molecular dynamics

Indexed keywords

ATP BINDING; ATP-BINDING SITE; B-RAF; CONFORMATIONAL CHANGE; IN-SILICO; MOLECULAR BASIS; MOLECULAR DYNAMICS SIMULATIONS; MOLECULAR INTERACTION FIELDS; MOLECULAR LEVELS; WILD TYPES;

ACTIVATION ANALYSIS; BINDING ENERGY; BINDING SITES; BIOCHEMISTRY; MOLECULAR DYNAMICS; PHOSPHORYLATION; TUMORS;

STEEL METALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; B RAF KINASE; LYSINE; SERINE; THREONINE;

ARTICLE; BINDING SITE; COMPUTER MODEL; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME BINDING; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN VARIANT;

ADENOSINE TRIPHOSPHATE; AMINO ACID SUBSTITUTION; BINDING SITES; COMPUTATIONAL BIOLOGY; HYDROGEN BONDING; MOLECULAR DYNAMICS SIMULATION; MUTANT PROTEINS; PHOSPHORYLATION; PROTEIN STRUCTURE, SECONDARY; PROTO-ONCOGENE PROTEINS B-RAF; SUBSTRATE SPECIFICITY;

EID: 76549115229     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2009.12.005     Document Type: Article

References (29)

1. Robinson M.J., and Cobb M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9 (1997) 180-186
2. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.W., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
3. Zhang B.H., and Guan K.L. Activation of B-RAF kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 19 (2000) 5429-5439
4. Dibb N.J., Dilworth S.M., and Mol C.D. Switching on kinases: oncogenic activation of B-RAF and PDGFR family. Nat. Rev. Cancer 4 (2004) 718-727
5. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer S.J., Barford D., and Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
6. Russon A.E., Torrisi E., Bevelacqua Y., Perrotta R., Libra M., McCubrey J.A., Spandidos D.A., Stivala F., and Malaponte G. Melanoma: molecular pathogenesis and emerging target therapies. Int. J. Oncol. 34 (2009) 1481-1489 (Review)
7. Grbovic O.M., Basso A.D., Sawai A., Ye Q., Friedlander P., Solit D., and Rosen N. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 57-62
8. Malumbres M., and Barbacid M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3 (2003) 459-465
9. Liao J.J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem. 50 (2007) 409-424
10. Moretti S., De Falco V., Tamburrino A., Barbi F., Tavano M., Avenia N., Santeusanio F., Santoro M., Macchiarulo A., and Puxeddu E. Insights into the molecular function of the inactived mutations of B-raf involving the DFG motif. Biochim. Biophys. Acta 1793 (2009) 1634-1645
11. De Falco V., Giannini R., Tamburrion A., Ugolini C., Lupi C., Puxeddu E., Santoro M., and Basolo F. Functional characterization of the Novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 93 (2008) 4398-4402
12. King A.J., Patrick D.R., Batorsky R.S., Ho M.L., Do H.T., Zhang S.Y., Kumar R., Rusnak D.W., Takle A.K., Wilson D.M., Hugger E., Wang L., Karreth F., Lougheed J.C., Lee J., Chau D., Stout T.J., May E.W., Rominger C.M., Schaber M.D., Luo L., Lakdawala A.S., Adams J.L., Contractor R.G., Smalley K.S., Herlyn M., Morrissey M.M., Tuveson D.A., and Huang P.S. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66 (2006) 11100-11105
13. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., and Bollag G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 3041-3046
14. Xie P., Streu C., Qin J., Bregman H., Pagano N., Meggers E., and Marmorstein R. The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase. Biochemistry 48 (2009) 5187-5198
15. V600E ligand inhibition, selectivity and conformational stability: an in silico study. Mol. Pharm. 6 (2009) 144-157
16. Fratev F., and Jónsdóttir S.O. An in silico study of the molecular basis of B-RAF activation and conformational stability. BMC Struct. Biol. 9 (2009) 47
17. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. The Protein Data Bank. Nucleic Acids Res. 28 (2000) 235-242
18. Marti-Renom M.A., Stuart A., Fiser A., Sánchez R., Melo F., and Sali A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 29 (2000) 291-325
19. Case D.A., Darden T.A., Cheatham III T.E., Simmerling C.L., Wang J., Duke R.E., Luo R., Merz K.M., Pearlman D.A., Crowley M., Walker R.C., Zhang W., Wang B., Hayik S., Roitberg A., Seabra G., Wong K.F., Paesani F., Wu X., Brozell S., Tsui V., Gohlke H., Yang L., Tan C., Mongan J., Hornak V., Cui G., Beroza P., Mathews D.H., Schafmeister C., Ross W.S., and Kollman P.A. AMBER 9 (2006), University of California, San Francisco
20. James C.P., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa .E., Chipot C., Skeel R.D., Kale L., and Schulten K. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26 (2005) 1781-1802
21. Berendsen H.J., Grigera J., and Straatsma T. The missing term in effective pair potentials. J. Phys. Chem. 91 (1987) 6269-6271
22. Ryckaert J.P., Ciccotti G., and Berendsen H.J.C. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 23 (1977) 327-341
23. Darden T., York D., and Pederson L. Particle mesh Ewald: an N.log(N) method for Ewald sums in large systems. J. Chem. Phys. 98 (1993) 10089-10092
24. Humphrey W., Dalke A., and Schulten K. VMD-Visual Molecular Dynamics. J. Mol. Graph. 14 (1996) 33-38
25. Goodford P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28 (1985) 849-857
26. Carosati E., Sciabola S., and Cruciani G. Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field. J. Med. Chem. 47 (2004) 5114-5125
27. Hanks S.K., and Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9 (1995) 576-596
28. Garnett M., and Marais R. Guilty as charged B-RAF is a human oncogene. Cancer Cell 6 (2004) 313-319
29. Cheung M., Sharma A., Madhunapantula S.V., and Robertson G.P. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 68 (2008) 3429-3439